{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1", "query": { "condition": "Phase 1" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18327, "total_pages": 1833, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-26T20:12:36.006Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04789655", "title": "Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myeloid" ], "interventions": [ { "name": "CC-96191", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 45, "start_date": "2021-06-16", "completion_date": "2025-04-14", "has_results": false, "last_update_posted_date": "2025-05-31", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Jacksonville, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT04789655" }, { "nct_id": "NCT03343626", "title": "Safety, Immunogenicity, and Dose Ranging Study of Inactivated Zika Virus Vaccine in Healthy Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Virus, Zika", "Zika Virus Disease", "Flavivirus Infections", "Healthy Participants" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "PIZV", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "49 Years", "sex": "ALL", "summary": "18 Years to 49 Years" }, "enrollment_count": 271, "start_date": "2017-11-13", "completion_date": "2020-11-24", "has_results": true, "last_update_posted_date": "2022-02-11", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 7, "location_summary": "Coral Gables, Florida • Miami, Florida • Lenexa, Kansas + 3 more", "locations": [ { "city": "Coral Gables", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Lenexa", "state": "Kansas" }, { "city": "Endwell", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03343626" }, { "nct_id": "NCT00003385", "title": "Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Fallopian Tube Cancer", "Ovarian Cancer", "Primary Peritoneal Cavity Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 48, "start_date": "1999-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-27", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 7, "location_summary": "Honolulu, Hawaii • Iowa City, Iowa • Bethesda, Maryland + 3 more", "locations": [ { "city": "Honolulu", "state": "Hawaii" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003385" }, { "nct_id": "NCT03697408", "title": "Itacitinib + Everolimus in Hodgkin Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Classical Hodgkin Lymphoma" ], "interventions": [ { "name": "Itacitinib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 23, "start_date": "2019-02-11", "completion_date": "2027-06", "has_results": true, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03697408" }, { "nct_id": "NCT05027815", "title": "Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV" ], "interventions": [ { "name": "Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Jeffrey Bluestone", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 7, "start_date": "2021-09-23", "completion_date": "2022-03-02", "has_results": true, "last_update_posted_date": "2023-06-05", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Columbus, Ohio", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05027815" }, { "nct_id": "NCT00124189", "title": "Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphoproliferative Diseases" ], "interventions": [ { "name": "GRN163L", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Geron Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2005-07", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2015-12-24", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 8, "location_summary": "Denver, Colorado • Hackensack, New Jersey • Buffalo, New York + 5 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Buffalo", "state": "New York" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00124189" }, { "nct_id": "NCT02257489", "title": "Phase 1 Study of ACE-083 in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Musculoskeletal Diseases" ], "interventions": [ { "name": "ACE-083", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "45 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "45 Years to 75 Years · Female only" }, "enrollment_count": 58, "start_date": "2014-09", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2022-09-23", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 1, "location_summary": "Lincoln, Nebraska", "locations": [ { "city": "Lincoln", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257489" }, { "nct_id": "NCT07444268", "title": "How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Hematologic Malignancies" ], "interventions": [ { "name": "DSP-5336", "type": "DRUG" }, { "name": "[14C]-DSP-5336", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sumitomo Pharma America, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2026-03-26", "completion_date": "2026-08", "has_results": false, "last_update_posted_date": "2026-04-08", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 2, "location_summary": "Chapel Hill, North Carolina • Houston, Texas", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07444268" }, { "nct_id": "NCT05557591", "title": "A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "BNT116", "type": "DRUG" }, { "name": "Cemiplimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regeneron Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-04-21", "completion_date": "2028-05-16", "has_results": false, "last_update_posted_date": "2026-05-06", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 9, "location_summary": "Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Farmington", "state": "New Mexico" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557591" }, { "nct_id": "NCT03136991", "title": "A Phase I, Safety Tolerability and Pharmacokinetics of AZD4831 to Treat Cardiovascular Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cardiovascular Disease" ], "interventions": [ { "name": "AZD4831", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 38, "start_date": "2017-05-15", "completion_date": "2017-11-22", "has_results": false, "last_update_posted_date": "2020-01-18", "last_synced_at": "2026-06-26T20:12:36.006Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136991" } ] }